Literature DB >> 25615721

Selenium and exposure to fibrogenic mineral dust: a mini-review.

Basilua Andre Muzembo1, Yoji Deguchi2, Nlandu Roger Ngatu3, Masamitsu Eitoku4, Ryoji Hirota4, Narufumi Suganuma4.   

Abstract

Individuals exposed to fibrogenic mineral dust may exhibit an impaired antioxidant system and produce high levels of reactive oxygen and nitrogen species through immune cells, contributing to the perturbation of immune cell function, inflammation, fibrosis and lung cancer. The lung diseases which are caused by inhalation of fibrogenic mineral dust, known as pneumoconioses, develop progressively and irreversibly over decades. At the moment there is no known cure. The trace element selenium has potent antioxidant and anti-inflammatory properties mediated mainly through selenoproteins. Research has demonstrated that selenium has the ability to protect against cardiovascular diseases; to kill cancer cells in vitro and reduce cancer incidence; and to immunomodulate various cellular signaling pathways. For these reasons, selenium has been proposed as a promising therapeutic agent in oxidative stress associated pathology that in theory would be beneficial for the prevention or treatment of pneumoconioses such as silicosis, asbestosis, and coal worker's pneumoconiosis. However, studies regarding selenium and occupational lung diseases are rare. The purpose of this study is to conduct a mini-review regarding the relationship between selenium and exposure to fibrogenic mineral dust with emphasis on epidemiological studies. We carried out a systematic literature search of English published studies on selenium and exposure to fibrogenic mineral dust. We found four epidemiological studies. Reviewed studies show that selenium is lower in individuals exposed to fibrogenic mineral dust. However, three out of the four reviewed studies could not confirm cause-and-effect relationships between low selenium status and exposure to fibrogenic mineral dust. This mini-review underscores the need for large follow-up and mechanistic studies for selenium to further elucidate its therapeutic effects.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asbestosis; Coal miner's pneumoconiosis; Pneumoconiosis; Selenium; Selenoproteins; Silicosis

Mesh:

Substances:

Year:  2015        PMID: 25615721     DOI: 10.1016/j.envint.2015.01.002

Source DB:  PubMed          Journal:  Environ Int        ISSN: 0160-4120            Impact factor:   9.621


  5 in total

1.  Investigation of selenium pretreatment in the attenuation of lung injury in rats induced by fine particulate matters.

Authors:  Jie Liu; Yingying Yang; Xuejiao Zeng; Liang Bo; Shuo Jiang; Xihao Du; Yuquan Xie; Rongfang Jiang; Jinzhuo Zhao; Weimin Song
Journal:  Environ Sci Pollut Res Int       Date:  2016-12-05       Impact factor: 4.223

Review 2.  Association of Selenium Levels with Preeclampsia: A Systematic Review and Meta-analysis.

Authors:  Hamdan Z Hamdan; Sumaia Z Hamdan; Ishag Adam
Journal:  Biol Trace Elem Res       Date:  2022-06-10       Impact factor: 3.738

3.  Nano-selenium and Macleaya cordata Extracts Improved Immune Function and Reduced Oxidative Damage of Sows and IUGR Piglets After Heat Stress of Sows in Late Gestation.

Authors:  Yuanfeng Li; Mingdong Fan; Quanyou Qiu; Yachao Wang; Xiaoyun Shen; Kui Zhao
Journal:  Biol Trace Elem Res       Date:  2022-01-12       Impact factor: 4.081

4.  Oxidative potential (OP) and mineralogy of iron ore particulate matter at the Gol-E-Gohar Mining and Industrial Facility (Iran).

Authors:  Naghmeh Soltani; Behnam Keshavarzi; Armin Sorooshian; Farid Moore; Christina Dunster; Ana Oliete Dominguez; Frank J Kelly; Prakash Dhakal; Mohamad Reza Ahmadi; Sina Asadi
Journal:  Environ Geochem Health       Date:  2017-03-09       Impact factor: 4.609

5.  Up-regulation of exosomal miR-125a in pneumoconiosis inhibits lung cancer development by suppressing expressions of EZH2 and hnRNPK.

Authors:  Lin Zhang; Jiangfeng Li; Changfu Hao; Wei Guo; Di Wang; Jianhui Zhang; Youliang Zhao; Shuyin Duan; Wu Yao
Journal:  RSC Adv       Date:  2018-07-25       Impact factor: 4.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.